This discovery supports the development of specific ASIC3 or combined ASIC1/3 blockers for the treatment of migraine-related pain and suggests a potential role in ASIC-dependent NO-mediated migraine triggering [88]. The gene discussed is ASIC1; the disease is migraine disorder.